A biosimilar PM(NOC) litigation proceeding was started recently involving the drug Filgrastim. The proceeding was started by Amgen Canada against Teva in T-989-12.

There has been similar litigation in the United States on the same drug which was settled. Beeser Ramamoorthy Law has a summary of the Notice of Application which involves allegations by Teva of non-infringement and invalidity.